Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
UC-NK101
- Development stage
- Preclinical
- Lead developer
- Universal Cells
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
UC-NK101 is a preclinical iPSC-derived Natural Killer (NK) cell therapy. It was part of Universal Cells' portfolio, a company acquired by Astellas Pharma in April 2022. Astellas's acquisition aimed to expand into the allogeneic cell therapy space, particularly for oncology. This therapy leverages induced pluripotent stem cells to generate NK cells, which are a type of immune cell known for their ability to recognize and kill cancer cells.
Beyond the preview
Go deeper on UC-NK101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on UC-NK101.